contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bbs-bioactive-bone-substitutes-oyj-changes-in-the-management-team-ceo-juliusz-rakowski-has-terminated-the-ceo-agreement

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BBS-Bioactive Bone Substitutes

BBS-Bioactive Bone Substitutes Plc | Company Release | December 18, 2024 at 13:00:00 EETBBS-Bioactive Bone Substitutes Oyj – Changes in the Management team: CEO Juliusz Rakowski has terminated...

<div class="mfn-header mfn-header-finland"><p>BBS-Bioactive Bone Substitutes Plc | Company Release | December 18, 2024 at 13:00:00 EET</p></div><div class="mfn-preamble"><p><strong>BBS-Bioactive Bone Substitutes Oyj – Changes in the Management team: CEO Juliusz Rakowski has terminated the CEO agreement</strong></p></div><div class="mfn-body"><p>CEO Juliusz Rakowski has terminated the CEO agreement between the Company and the CEO. Rakowski will continue in his position until February 28, 2025.</p><p>CEO Juliusz Rakowski: "I am grateful for the opportunity to be part of this journey and to lead talented people across various departments in the organization. I thank the Board, shareholders, partners, and the Company's dedicated employees for their cooperation."</p></div><div class="mfn-footer mfn-ad783d902722"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Pekka Jalovaara, the Chairman of the Board<br>+358 50 5529 275<br>pekka.jalovaara@bbs-artebone.fi</p></div><div class="mfn-footer mfn-67c8b2406f27"><p><strong class="mfn-heading-1">Distribution</strong><br>Nasdaq Helsinki<br><a rel="noopener" href="https://www.globenewswire.com/Tracker?data=dTX6KuwjXtC9yntip5ccELHgyMLbOC8p_qwAud8wR_OwuwTNIX6JB9T-9u2qDUKExAyUvAxRxfba9dWlnEvLjYC4hCeAo5EaIC_bkSh7hyM33b3gIm16ZVkdAzBgSsOw">https://www.bbs-artebone.fi/</a></p></div><div class="mfn-footer mfn-1586e9e67a6a"><p><strong class="mfn-heading-1">Certified Advisor:</strong><br>Nordic Certified Adviser AB,<br>+46 70 551 67 29,<br><a rel="noopener" href="mailto:info@certifiedadviser.se">info@certifiedadviser.se</a></p></div><div class="mfn-footer mfn-about mfn-838eb0731ac0"><p><strong class="mfn-heading-1">BBS in brief</strong><br><em>BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.</em><em><br></em><br><em>BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.</em><em><br></em><br><em>More information: </em><em><a rel="noopener" href="http://www.bbs-artebone.fi/">www.bbs-artebone.fi</a></em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/03aed136-d912-41cf-bd3b-7a9618fb3fe6/bbs-bioactive-bone-substitutes-oyj-changes-in-the-management-team-ceo-juliusz-rakowski-has-terminated-the-ceo-agreement.pdf" class="mfn-generated mfn-primary">BBS-Bioactive Bone Substitutes Oyj – Changes in the Management team: CEO Juliusz Rakowski has terminated the CEO agreement</a></p></div>

BBS-Bioactive Bone Substitutes Oyj – Changes in the Management team: CEO Juliusz Rakowski has terminated the CEO agreement